undamentalytics Newsletter
Sign in

Arcutis Biotherapeutics, Inc. income statement

In fiscal 2025, Arcutis Biotherapeutics, Inc. reported revenue of $376m, up 91.3% on the year before, operating income of −$12.2m (a -3.3% margin) and net income of −$16.1m, or −$0.13 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Revenue00460197376464
Cost of revenue—015193741
Gross profit—0355177339423
Research and development115146182111767791
Selling, general and administrative—61122185229275298
General and administrative21——————
Operating income−137−207−302−241−128−1234
Interest expense001630271214
Income tax0003111
Net income−136−206−311−262−140−1629
Diluted EPS−$3.80−$4.18−$5.66−$3.78−$1.16−$0.13—
Diluted shares (average)36m49m55m69m121m127m—
EBITDA−137−206−301−240−128−12—

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

Head to head: ARQT vs CRMDARQT vs KRYSARDX vs ARQTADMA vs ARQT

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Arcutis Biotherapeutics, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Arcutis Biotherapeutics, Inc.